Compounded · Dual GLP-1 / GIP

Tirzepatide Injection

When semaglutide alone hasn't been enough.

Tirzepatide acts on two appetite-regulating hormone pathways — GLP-1 and GIP. For many women in midlife who plateaued on semaglutide or who started later in life, the dual mechanism makes the difference.

  • Once-weekly subcutaneous injection — 30 seconds, at home
  • Dual GLP-1 / GIP receptor activity
  • Compounded by a state-licensed U.S. pharmacy
  • Includes clinician oversight, dose escalation, and side-effect support
  • Direct-to-door · cancel anytime on monthly · save more on 6 or 12-month plans
Start your assessment
Compounded tirzepatide injection — Cypress Health

Why tirzepatide

Two receptors. One injection. A different conversation.

Compounded tirzepatide injection for weight loss

Semaglutide acts on the GLP-1 receptor — one of two pathways involved in regulating appetite, satiety, and metabolism. Tirzepatide acts on both GLP-1 and GIP. The dual mechanism is delivered with the same once-weekly cadence.

For some women in midlife, the dual mechanism may be a fit when other approaches haven't been a match. Whether that's true for you isn't something we can promise — only your clinician can determine appropriateness, based on your medical history, current medications, and goals.

The intake is the first step. Outcomes vary; tirzepatide is not appropriate for everyone.

Dosing & what to expect

A measured start. Adjusted as you go.

1
Weeks 1–4 · Starting dose
2.5 mg once weekly. Most patients tolerate this well; mild GI symptoms are common in the first week or two and typically settle.
2
Weeks 5+ · Dose escalation
Your clinician adjusts your dose based on response and tolerance — typically 5 mg, 7.5 mg, 10 mg, with options up to 15 mg as appropriate.
3
Ongoing · Care, not just refills
Your plan includes ongoing clinician oversight, dose adjustment, side-effect support, and lab review when needed. We don't disappear after the first ship.

Side effects & safety

What to know before you start.

Woman reviewing health information at home

Most common: nausea, decreased appetite, mild diarrhea, constipation, fatigue. These are typically dose-related and most pronounced in the first week of each new dose.

Less common but important: pancreatitis, gallbladder issues, low blood sugar (especially if you also take insulin or sulfonylureas). Tell your clinician about all current medications.

Muscle mass during treatment: GLP-1 therapy can be associated with loss of lean mass, particularly in women in midlife. Your clinician will discuss strategies to protect muscle — typically resistance training and adequate dietary protein — as part of your care plan.

Not appropriate if: you have a personal or family history of medullary thyroid carcinoma or MEN2; you're pregnant, planning pregnancy, or breastfeeding; or you have severe GI disease or end-stage organ disease.

Compounded medication notice
Compounded tirzepatide is dispensed by state-licensed U.S. pharmacies in FDA-regulated facilities under the patient-specific 503A exception. It is not FDA-approved as a finished product. Your clinician will determine whether it is appropriate for your specific health profile.

Clinical evidence

In SURMOUNT-1 (Jastreboff et al., NEJM 2022), injectable tirzepatide produced up to ~20.9% body weight loss at the 15 mg weekly dose over 72 weeks — the largest published trial of a dual GLP-1/GIP receptor agonist for weight management.

Compounded tirzepatide uses the same active ingredient under the 503A exception. Outcomes from branded clinical trials cannot be directly attributed to compounded preparations.

Questions

Answers to
common questions.

How is compounded tirzepatide different from Mounjaro or Zepbound?
Same active ingredient, prepared per-patient under the 503A exception — not FDA-approved as a finished product.
Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are FDA-approved branded versions of injectable tirzepatide manufactured by Eli Lilly. Compounded tirzepatide is prepared per-patient by a state-licensed U.S. pharmacy under the 503A exception — the same active ingredient, but not FDA-approved as a finished product. Branded versions may be the right fit for some patients; for others, compounded is more accessible while remaining clinically appropriate. Your clinician will help you choose.
How does tirzepatide compare to semaglutide?
Dual GLP-1/GIP mechanism — greater average weight loss in published trials.
Tirzepatide acts on two appetite-regulating hormone pathways — GLP-1 and GIP — while semaglutide acts on GLP-1 alone. The dual mechanism translated to greater average weight loss in published trials. SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed up to ~20.9% body weight loss at the 15 mg weekly dose over 72 weeks. For women who've plateaued on semaglutide or who are starting GLP-1 therapy later in life, tirzepatide is often considered. Outcomes from branded clinical trials cannot be directly attributed to compounded preparations.
When am I charged?
Not until a clinician confirms your eligibility — typically within 24–48 hours.
You're not charged when you submit. Your card is securely saved while a licensed clinician reviews your assessment, typically within 24 to 48 hours. If approved, you'll receive an email confirmation before any charge. If not approved, you're not charged.
How will it ship — and does it need refrigeration?
Cold-chain via UPS or FedEx; refrigerate on arrival.
Once approved, the pharmacy ships within 1–2 business days via UPS or FedEx, Monday through Friday. Cold-chain shipping is two-day in cooler months and overnight when temperatures are warm. Compounded tirzepatide should be refrigerated on arrival; if it ever arrives frozen, allow it to thaw at room temperature before use. If a shipment is lost or arrives damaged, we'll reship at no cost.
Will I need to stay on treatment after I reach my goal?
Most people regain weight without a structured maintenance plan. We plan that step with you.
The available evidence shows most people regain weight when GLP-1 or GLP-1/GIP therapy stops without a structured maintenance plan; the SURMOUNT-4 withdrawal trial (Aronne et al., JAMA 2024) showed weight regain after tirzepatide was discontinued. Options include stepping down to a lower maintenance dose, weaning off with structured resistance training and protein-forward eating to protect lean mass, or continuing at full dose. The right path is decided with you when the time comes — not around you.
Can I cancel? Will my insurance, HSA, or FSA cover this?
Cancel anytime on monthly. HSA/FSA usually accepted; insurance generally doesn't cover compounded.
The 1-month plan can be cancelled at any time. The 6 and 12-month plans are committed terms billed monthly — cancel future renewals after the term ends. Compounded tirzepatide is generally not insurance-reimbursable because it's prepared per-patient rather than as an FDA-approved finished product. HSA or FSA cards are typically accepted for prescription medications; check with your benefits administrator to confirm eligibility for compounded medications under your specific plan.

See if tirzepatide is right for you.

The 3-minute medical screener is free. If you're a candidate, your clinician follows up within 24 hours — before any charges are processed.

Start your assessment